Get the Stockscreener App
4.12
0.49%
0.02
Nervgen Pharma Corp stock is traded at $4.12, with a volume of 58,279.
It is up +0.49% in the last 24 hours and down -27.08% over the past month.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
See More
Previous Close:
$4.10
Open:
$4.16
24h Volume:
58,279
Relative Volume:
1.10
Market Cap:
$326.36M
Revenue:
-
Net Income/Loss:
$-18.50M
P/E Ratio:
-15.91
EPS:
-0.259
Net Cash Flow:
$-11.89M
1W Performance:
+7.57%
1M Performance:
-27.08%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.00
$4.19
1-Week Range:
$3.8401
$4.24
52-Week Range:
$3.73
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
4.12 | 324.77M | 0 | -18.50M | -11.89M | -0.259 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nervgen Pharma Corp Stock (NGEN) Latest News
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program - TipRanks
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - GlobeNewswire
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium - Yahoo! Finance Canada
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - MSN
NervGen Pharma appoints Dr. Adam Rogers as CEO and president By Investing.com - Investing.com India
NervGen Pharma appoints Dr. Adam Rogers as CEO and president - Investing.com
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal - TipRanks
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury - marketscreener.com
NervGen Pharma names Adam Rogers as CEO - The Pharma Letter
NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase - TipRanks
NervGen appoints Rogers as CEO to lead neuroreparative drug development By Investing.com - Investing.com Australia
NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase - TipRanks
NervGen Pharma Appoints New CEO Adam Rogers - Intellectia AI
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291 - GuruFocus
NervGen Pharma Names Adam Rogers as CEO - marketscreener.com
NervGen appoints Rogers as CEO to lead neuroreparative drug development - Investing.com
NervGen Pharma Corp appoints Adam Rogers as chief executive officer - marketscreener.com
NervGen Pharma Corp. Appoints Adam Rogers as Chief Executive Officer, Effective February 9, 2026 - marketscreener.com
New drug may help spinal cord injury patients regain function and hope - WGN-TV
When Will NervGen Pharma Corp. (CVE:NGEN) Breakeven? - Yahoo Finance
Johnson & Johnson receives CHMP positive opinion for AKEEGA - marketscreener.com
Analysts Expect Breakeven For NervGen Pharma Corp. (CVE:NGEN) Before Long - simplywall.st
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
NervGen Pharma Rings the Closing Bell - Nasdaq
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing - GlobeNewswire
NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment - MSN
NervGen Pharma Begins Trading on Nasdaq Today - Sahm
Is NervGen Pharma Corp. (9UA) stock good for wealth creationJuly 2025 Movers & Weekly High Conviction Trade Ideas - Улправда
NervGen Pharma Debuts On Nasdaq - Nasdaq
NervGen Pharma to Begin Trading on Nasdaq - marketscreener.com
NervGen Pharma Lists on Nasdaq to Support Late-Stage Push for Spinal Cord Injury Drug - TipRanks
NervGen Pharma Gets Approval for Listing on Nasdaq - marketscreener.com
NervGen Pharma Brief: Begins Trading on Nasdaq Today - marketscreener.com
Sector Update: Health Care Stocks Edge Higher Late Afternoon - marketscreener.com
Sector Update: Health Care Stocks Mixed Late Afternoon - marketscreener.com
This Company’s Drug May Help Regenerate Injured Spinal Cords - Forbes
NervGen Pharma Files SEC Registration to Advance Strategic Growth - TipRanks
NervGen Pharma Proposes Amendment to Warrant Terms - TipRanks
This Canadian biotech stock is looking to treat spinal cord injuries - Cantech Letter
NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment - TipRanks
Data back spinal injury bid from Nervgen in phase Ib/IIa - BioWorld MedTech
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development - TMX Newsfile
NervGen Pharma Secures $10 Million to Propel Nasdaq Listing and NVG-291 Development - TipRanks
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development - TMX Newsfile
Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth? - Yahoo Finance
Pennsylvania man says experimental drug has helped him recover from cycling accident - CBS News
Nervgen Pharma’s NVG-291 Study: A Potential Breakthrough in Spinal Cord Injury Treatment - TipRanks
NervGen Pharma price target chopped at Research Capital - Cantech Letter
NervGen: A High-Stakes Bet on a Groundbreaking Nerve Repair Drug - NAI500
TSX Penny Stocks To Consider In August 2025 - Yahoo Finance
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury - Yahoo Finance
Nervgen Pharma Corp Stock (NGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):